Long-term PEACE-1 data showed that adding abiraterone acetate plus prednisone to standard of care extended median OS by 1.5 years in de novo metastatic CSPC.
|Slideshows|August 15, 2015
Top Ten ICD-10 Tips for Oncology Practices
Author(s)Michelle Cavanaugh, RN, CPC
In the long term, ICD-10 has the potential to benefit oncology through improved data collection, but right now, practices just need to focus on preparing for the change. Here are 10 tips for oncologists.
Advertisement
Advertisement
Related to this article
Adding perioperative apalutamide and ADT to radical prostatectomy reduced the risk of an oncologic event or death by 62% in high-risk prostate cancer.
The phase 3 DeLLphi-305 trial may support tarlatamab plus durvalumab as a new standard-of-care frontline maintenance option in extensive-stage SCLC.
Full INTerpath-001 data at ESMO 2026 detail OS, subgroup, and safety results with intismeran plus pembrolizumab in resected stage IIB to IV melanoma.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
In the phase 3 TANGENT trial, an 8-week course of emactuzumab improved objective response rate vs placebo in patients with tenosynovial giant cell tumor.
In an exploratory KEYNOTE-B15 analysis, ctDNA clearance was higher with enfortumab vedotin plus pembrolizumab than with cisplatin and gemcitabine.
Advertisement
Advertisement
Trending on CancerNetwork
1
INTerpath-001 Data Detail Survival, Subgroup, and Safety Findings in Melanoma
2
Tarlatamab Maintenance Combo Extends Survival in Extensive-Stage SCLC
3
Belantamab Mafodotin Combo Yields High MRD Negativity in NDMM
4
Apalutamide/ADT Improves EFS vs Surgery Alone in High-Risk Prostate Cancer
5